Безопасность совместного применения четырехвалентной конъюгированной вакцины против менингококковой инфекции серогрупп А, С, Y, W-135 с другими вакцинными препаратами: проспективное исследование серии случаев среди детей здоровых и с различными отклонениями в состоянии здоровья

Лейла Сеймуровна Намазова-баранова, Д. А. Новикова, Марина Владиславовна Федосеенко, Анна Геннадьевна Гайворонская, Н. Е. Ткаченко, Татьяна Альбертовна Калюжная, Ф. Ч. Шахтахтинская, М. И. Броева
{"title":"Безопасность совместного применения четырехвалентной конъюгированной вакцины против менингококковой инфекции серогрупп А, С, Y, W-135 с другими вакцинными препаратами: проспективное исследование серии случаев среди детей здоровых и с различными отклонениями в состоянии здоровья","authors":"Лейла Сеймуровна Намазова-баранова, Д. А. Новикова, Марина Владиславовна Федосеенко, Анна Геннадьевна Гайворонская, Н. Е. Ткаченко, Татьяна Альбертовна Калюжная, Ф. Ч. Шахтахтинская, М. И. Броева","doi":"10.15690/VSP.V16I2.1717","DOIUrl":null,"url":null,"abstract":"Meningococcal infection is an acute disease caused by Neisseria meningitidis, which proceeds with a diverse clinical aspect from nasopharyngitis to meningococcal meningitis and meningococcemia. Since 2014, a tetravalent meningococcal conjugate vaccine has been registered in Russia. This vaccine creates protection against serogroups A, C, W-135, Y and can be used from the age of nine months to 55 years. The actual issue is a vaccine tolerability, including when combined with other vaccine preparations. Objective: Our aim was to evaluate the safety of a tetravalent meningococcal conjugate vaccine against serogroups A, C, Y and W-135 when it is combined with other vaccine preparations. Methods. A prospective full-design study assessed the tolerability of immunization with a meningococcal conjugate vaccine, both in case of monovaccination and in combination with a pneumococcal 13-valent conjugate vaccine, measles-mumps-rubella, viral hepatitis A, influenza, and chicken pox vaccines. Results. 97 children aged from 9 months to 18 years were vaccinated, 20 of them were healthy and 77 had medical issues (with allergic pathology, ENT diseases, cardiovascular and nervous system diseases, lung diseases as well as orphan diseases). Among vaccinated children, general reactions were observed in 3/97 (3.1%) children, local reactions — in 5 (5.2%). The post-vaccination period passed asymptomatically and uneventfully in the prevailing majority of children vaccinated with a tetravalent meningococcal conjugate vaccine (in 91, 93.8%). Conclusion. The immunization with a tetravalent meningococcal conjugate vaccine against serogroups A, C, Y, W-135 is well tolerated, both in case of monovaccination and in combination with other vaccine preparations, in healthy children of different age groups and in patients with different health status.","PeriodicalId":10919,"journal":{"name":"Current Paediatrics","volume":"26 1","pages":"156-162"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Paediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15690/VSP.V16I2.1717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Meningococcal infection is an acute disease caused by Neisseria meningitidis, which proceeds with a diverse clinical aspect from nasopharyngitis to meningococcal meningitis and meningococcemia. Since 2014, a tetravalent meningococcal conjugate vaccine has been registered in Russia. This vaccine creates protection against serogroups A, C, W-135, Y and can be used from the age of nine months to 55 years. The actual issue is a vaccine tolerability, including when combined with other vaccine preparations. Objective: Our aim was to evaluate the safety of a tetravalent meningococcal conjugate vaccine against serogroups A, C, Y and W-135 when it is combined with other vaccine preparations. Methods. A prospective full-design study assessed the tolerability of immunization with a meningococcal conjugate vaccine, both in case of monovaccination and in combination with a pneumococcal 13-valent conjugate vaccine, measles-mumps-rubella, viral hepatitis A, influenza, and chicken pox vaccines. Results. 97 children aged from 9 months to 18 years were vaccinated, 20 of them were healthy and 77 had medical issues (with allergic pathology, ENT diseases, cardiovascular and nervous system diseases, lung diseases as well as orphan diseases). Among vaccinated children, general reactions were observed in 3/97 (3.1%) children, local reactions — in 5 (5.2%). The post-vaccination period passed asymptomatically and uneventfully in the prevailing majority of children vaccinated with a tetravalent meningococcal conjugate vaccine (in 91, 93.8%). Conclusion. The immunization with a tetravalent meningococcal conjugate vaccine against serogroups A, C, Y, W-135 is well tolerated, both in case of monovaccination and in combination with other vaccine preparations, in healthy children of different age groups and in patients with different health status.
血清组a、c、Y、W-135和其他疫苗共享安全:对健康儿童和不同健康状况的一系列病例进行积极研究
脑膜炎球菌感染是一种由脑膜炎奈瑟菌引起的急性疾病,其临床表现多样,从鼻咽炎到脑膜炎球菌性脑膜炎和脑膜炎球菌血症。自2014年以来,俄罗斯已注册了一种四价脑膜炎球菌结合疫苗。该疫苗可针对A、C、W-135和Y血清群提供保护,可在9个月至55岁期间使用。实际问题是疫苗的耐受性,包括与其他疫苗制剂联合使用时。目的:我们的目的是评估一种针对a、C、Y和W-135血清群的四价脑膜炎球菌结合疫苗与其他疫苗制剂联合使用的安全性。方法。一项前瞻性全设计研究评估了脑膜炎球菌结合疫苗的免疫耐受性,包括单独接种和与肺炎球菌13价结合疫苗、麻疹-腮腺炎-风疹、病毒性甲型肝炎、流感和水痘疫苗联合接种。结果:97名9个月~ 18岁的儿童接种疫苗,其中健康儿童20人,有医学问题(过敏病理、耳鼻喉科疾病、心血管和神经系统疾病、肺部疾病和孤儿病)的儿童77人。在接种疫苗的儿童中,3/97(3.1%)儿童出现全面性反应,5(5.2%)儿童出现局部反应。在接种四价脑膜炎球菌结合疫苗的绝大多数儿童中,接种后期无症状且平安无事(91.93.8%)。结论。针对a、C、Y、W-135血清群的四价脑膜炎球菌结合疫苗免疫,在不同年龄组的健康儿童和不同健康状况的患者中,无论是单独接种还是与其他疫苗制剂联合接种,都具有良好的耐受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信